Skip to main content

Table 1 Characteristics of pancreatic ductal adenocarcinoma in patients with either resectable or nonresectable tumors

From: Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer

Characteristics Resectable tumor (n= 230) Non-resectable tumor (n= 458) P value
Age (years) 62.1 ± 11.1 64.0 ± 12.0 0.047
  <65 136 (59.1%) 226 (49.3%) 0.015
  ≥65 94 (40.9%) 232 (50.7%)  
Sex    0.749
  Male 143(62.2%) 279 (60.9%)  
  Women 87 (37.8%) 179 (37.1%)  
Symptoms    0.018
  Yes 225 (97.8%) 457 (99.8%)  
  No 5 (2.2%) 1 (0.2%)  
Physical findings    0.979
  Yes 166 (72.2%) 331 (72.3%)  
  No 64 (27.8%) 127 (27.7%)  
Bilirubin (mg/dl) 7.5 ± 9.1 7.2 ± 8.5 0.574
  ≤1.3 80 (36.5) 177 (42.3) 0.155
  >1.3 139 (63.5) 241 (57.7)  
Albumin (g/dl) 3.77 ± 0.65 3.63 ± 0.71 0.025
  ≤3.5 61 (33.0%) 149 (43.3%) 0.020
  >3.5 124 (67.0%) 195 (56.7%)  
AST (U/L) 112.9 ± 146.8 84.8 ± 99.2 0.011
  ≤68 110 (49.1%) 250 (60.1%) 0.008
  >68 114 (50.9%) 166 (39.9%)  
CEA (ng/ml) 6.1 ± 8.1 13.5 ± 48.0 0.008
  ≤5 115 (67.6%) 180 (58.4%) 0.047
  >5 55 (32.4%) 128 (41.6%)  
CA 19–9 (U/ml) 1,229.6 ± 4,680.4 1,616.4 ± 5,253.1 0.425
  ≤37 48 (27.1%) 46 (16.5%) 0.007
  >37 129 (72.9%) 232 (83.5%)  
Operation time (minutes) 426.0 ± 155.3 219.2 ± 172.4 <0.0001
  ≤240 31 (13.9%) 285 (68.3%) <0.0001
  >240 192 (86.1%) 132 (31.7%)  
Complication    0.003
  Yes 55 (23.9%) 67 (14.6%)  
  No 175 (76.1%) 391 (85.4%)  
Death    0.017
  Yes 7 (3.0%) 36 (7.6%)  
  No 223 (97.0%) 423 (92.4%)  
Tumor size (cm) 4.6 ± 3.6 6.2 ± 3.5 <0.0001
  ≤3 94 (42.7%) 24 (15.8%) <0.0001
  >3 126 (57.3%) 128 (84.2%)  
Location    0.111
  Head of pancreas 165 (71.7%) 301 (65.7%)  
  Not at head of pancreas 65 (28.3%) 157 (34.3%)  
Differentiation    0.0002
  Well 83 (36.1%) 134 (29.3%)  
  Moderate 105 (45.7%) 173 (37.8%)  
  Poor 35 (15.2%) 103 (22.5%)  
Others 7 (3.0%) 48 (10.5%)  
Post-op C/T    <0.0001
  Yes 121 (52.6%) 163 (35.6%)  
  No 109 (47.7%) 295 (64.4%)  
Post-op R/T    0.255
  Yes 17 (7.4%) 46 (10.0%)  
  No 213 (92.6%) 412 (90.0%)  
  1. AST: aspartate aminotransferase; CEA: carcinoembryonic antigen; CA 19–9: carbohydrate antigen 19–9; Post-op C/T: postoperative chemotherapy; Post-op R/T: postoperative radiotherapy; Others: mixed tumor differentiation.